Navigation Links
Cardium Announces Investor Presentation and Corporate Update Webcast
Date:12/3/2008

SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) announces that the Company will be presenting a webcast providing an investor presentation, corporate update and review of its ongoing business strategies and plans. The webcast will be presented following the close of market today at 4:30 PM (Eastern Time) and can be accessed at http://www.investorcalendar.com/IC/CEPage.asp?ID=138418 at that time. The webcast will also be accessible for the following thirty days via the Investors section at "Calendar of Events" on the Company's website at http://www.cardiumthx.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

Forward-Looking Statements in Webcast

Except for statements of historical fact, the matters discussed in the webcast are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. Actual results may also differ substantially from those described in or contemplated by the webcast due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties inherent in the conduct of human clinical trials, including the timing, costs and results of such trials, our limited experience in the development, testing and marketing of therapeutic hypothermia devices, uncertainties regarding potential corporate development partners, our dependence upon proprietary technology, uncertainties regarding ongoing needs to support product development programs and other cash expenditures, our history of operating losses and accumulated deficits, risks and uncertainties related to our ability to raise cash under difficult capital market conditions, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2008 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit http://www.cardiumthx.com.

Cardium Therapeutics(TM) and Generx(TM) are trademarks of Cardium

                              Therapeutics, Inc.
Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM) and Excellarate(TM) are
                     trademarks of Tissue Repair Company.
       InnerCool Therapies(R), InnerCool(R), Celsius Control System(R),
  RapidBlue(TM), CoolBlue(TM), Accutrol(R), Temperature Control Element(R),
      TCE(R) and UroCool(TM) are trademarks of InnerCool Therapies, Inc.

'/>"/>
SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardium Completes $6.0 Million Financing
2. Cardium Announces InnerCools Endovascular Cooling to be Featured on Science Channels Series Cool Stuff: How It Works
3. Cardiums InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems
4. Cardium Reports on Recent Highlights and Financial Results
5. An international first at the CHUM - Promising treatment in regeneration of the myocardium through the use of stem cells
6. AANMA Announces Launch of Free Web-Based Education Program for Patients Transitioning From CFC to HFA Inhalers
7. Lucas Group Announces Their Executive Recruitment Military Hiring Conference Schedule for December 2008
8. Axiom Consulting Partners Announces the Results of its Return On Sales Investment Survey
9. United American Healthcare Corporation Announces Stock Repurchase Program
10. eOn Communications Announces GSA Contract
11. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent ... cancer deaths. More than 10,000 people are expected to die of melanoma this year. The ... the one of the most commonly diagnosed cancers in young women. A recent breakthrough in ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces that Boston ... and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its ... is a newly patented safety device secured by nasal surgeons onto the floor ...
(Date:4/29/2016)... ... April 29, 2016 , ... Innovations with Ed Begley ... upcoming episode, airing third quarter 2016 via Discovery Channel. Dates and show times ... Dairy Products, located in Greenwood, Wisconsin applies product research and development and continuous ...
(Date:4/29/2016)... ... April 29, 2016 , ... The infertility specialists at ... Sanaz Ghazal, and Dr. Daniel A. Potter -- are proud of the recent release ... Technology (SART). In April, SART published the latest verified data for 375 ...
(Date:4/29/2016)... ... April 29, 2016 , ... International Dehydrated Foods, Inc. (IDF™) will attend ... 4 at the Doubletree by Hilton Hotel in Oak Brook, Illinois. The two-day event ... technologies for protein ingredients. , At the seminar, IDF™ will offer samples of its ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016  Marking its one year anniversary ... ovarian cancer risk test, Color Genomics ... that highly impact the most common hereditary cancers ... Color Test analyzes hereditary cancer risks for breast, ... cancers. The Color Test is physician ordered and ...
(Date:4/28/2016)... YORK , April 28, 2016  The blood ... 275 million dollars, according to Kalorama Information and The ... typing, immunoassays and nucleic acid testing.  The healthcare research ... made progress in developing blood collection stations and in ... made in Kalorama Information,s report, Blood Testing ...
(Date:4/28/2016)... WARSAW, Ind., April 28, 2016 , Net ... a reported basis over the prior year period, and an ... basis , Diluted EPS for the first quarter were ... period, and $2.00 adjusted, an increase of 29.9% over the ... revenue and adjusted earnings guidance for 2016 Zimmer ...
Breaking Medicine Technology: